Список литературы

Abe A, Arend LJ, Lee L, Lingwood C, Brady RO, Shayman JA. Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. Kidney Int 2000a;57:446-54

Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 2000b;105:1563-71

Altarescu G, Elstein D. Coexistence of Fabry disease and Crohn's disease: a case report. Inflamm Bowel Dis 2005;11:87-8
Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001;32:1559-62

Amann-Vesti BR, Gitzelmann G, Widmer U, Bosshard NU, Steinmann B, Koppensteiner R. Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol 2003;1:185-9

Anderson W. A case of angiokeratoma. Br J Dermatol 1898;18:113-17

Argoff CE, Barton NW, Brady RO, Ziessman HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 1998;19:887-91

Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Fabry disease: twenty-two novel mutations in the а-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 2000;48:227-35

Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54

Baccaglini L, Schiffmann R, Brennan MT, Lancaster HE Jr, Kulkarni AB, Brahim JS. Oral and craniofacial findings in Fabry's disease: a report of13 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:415-19

Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J InheritMetabDis 2003;26:617-27

Bagdade JD, Parker F, Ways PO, Morgan TE, Lagunoff D, Eidelman S. Fabry's disease. A correlative clinical, morphologic, and biochemical study. Lab Invest 1968;18:681-8

Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005;85:255-9

Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA. Silicon nephropathy mimicking Fabry's disease. Am J Nephrol 1983;3:279-84

Beck M. Demographics of FOS – the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis Ltd; 2006: p. 155-61

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-44

Beck M, Ries M. Fabry disease: clinical manifestations, diagnosis and therapy. Oxford: OCC Europe Ltd; 2001

Bekri S, Enica A, Ghafari T, Plaza G, Champenois I, Choukroun G et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:c33-38

Bennett RL, Hart KA, O'Rourke E, Barranger JA, Johnson J, MacDermot KD et al. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns 2002;11:121-46

Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H et al. Fabry disease: six gene rearrangements and an exonic point mutation in the а-galactosidase gene. J Clin Invest 1989;83:1390-9

Beutler E, Kuhl W. Biochemical and electrophoretic studies of а-galactosidase in normal man, in patients with Fabry's disease, and in Equidae. Am J Hum Genet 1972;24:237-49

Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human а-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci USA 1988;85:3903-7

Страницы:

←

1

2 3 4 5 6 7 8 9 10 →

из 12